 |
 |
 |
 |
 |
Subject: Depression in PD: Treatment (PD Congress 2001) Date: 8/4/2001 E-MOVE reports from the 14th International Congress on Parkinson's Disease, Helsinki July 28-Aug 1. Poster and Platform session numbers refer to those in the abstract book, published in Parkinsonism and Related Disorders 2001;7(Supplement).1. Depression in Parkinson's disease: An eight-month, randomized, open-label national multi-centre comparative study of pramipexole and pergolide I Rektorova, I Rektor, M Bares V Dostal, E Ehler, Z Fanfrdlova, J Fiedler, H Klajblova, P Kulistak, Pessner, J Svatova, K Urbanek, J Veliskova P-TU-229 Pramipexole improves depression independently of motor benefit, according to this report. Forty-one patients with mild-to-moderate depression and taking levodopa received either pramipexole or pergolide up to 4.5 mg/day for six weeks. Motor improvement was significant on both treatments, but was not different between the two treatments. Both groups had a significant reduction in depression on the Zung self-rated scale. Pramipexole-treated patients, but not pergolide-treated patients, showed significant reduction in depression on the MADRS scale, rated by a blinded psychologist, effects which remained after accounting for motor improvements. 2. MAO-A and MAO-B inhibitors in the treatment of depression in Parkinson's disease A Takats, E Szombathelyi, MI Farsang P-TU-242 Fifty-two patients on 10 mg/day selegiline received 450 mg/day of the MAO-A inhibitor moclobemide. Depression scores improved in 41 patients after 3 months of treatment. Eleven patients withdrew, due to sleep disturbance, increased blood pressure, or lack of response. --- Funding for E-MOVE meeting reports is provided in part by unrestricted educational grants from Allergan Inc., Elan Pharmaceuticals, and Pharmacia Corporation. E-MOVE Editor: Richard Robinson, NASW, WE MOVE
|
|
| All contents copyright © WE MOVE 2010. This page last modified 2/25/2009. | |